Literature DB >> 11906945

Cyclo-oxygenase-2 inhibition and exacerbation of myocardial dysfunction--protection with nitric oxide?

Gordon Letts1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2002        PMID： 11906945      PMCID： PMC1573249          DOI： 10.1038/sj.bjp.0704584

Source DB:  PubMed          Journal:  Br J Pharmacol        ISSN： 0007-1188            Impact factor:   8.739


× No keyword cloud information.
  13 in total

Review 1.  The coxibs, selective inhibitors of cyclooxygenase-2.

Authors:  G A FitzGerald; C Patrono
Journal:  N Engl J Med       Date:  2001-08-09       Impact factor: 91.245

Review 2.  Cyclooxygenase-2: its rich diversity of roles and possible application of its selective inhibitors.

Authors:  M Katori; M Majima
Journal:  Inflamm Res       Date:  2000-08       Impact factor: 4.575

Review 3.  Nitric oxide insufficiency, platelet activation, and arterial thrombosis.

Authors:  J Loscalzo
Journal:  Circ Res       Date:  2001-04-27       Impact factor: 17.367

Review 4.  Nitric oxide-releasing NSAIDs: a review of their current status.

Authors:  S Fiorucci; E Antonelli; J L Burgaud; A Morelli
Journal:  Drug Saf       Date:  2001       Impact factor: 5.606

5.  S-nitrosylated tissue-type plasminogen activator protects against myocardial ischemia/reperfusion injury in cats: role of the endothelium.

Authors:  J A Delyani; T O Nossuli; R Scalia; G Thomas; D S Garvey; A M Lefer
Journal:  J Pharmacol Exp Ther       Date:  1996-12       Impact factor: 4.030

6.  Acute hypertension after nitric oxide synthase inhibition is mediated primarily by increased endothelin vasoconstriction.

Authors:  J D Banting; P Friberg; M A Adams
Journal:  J Hypertens       Date:  1996-08       Impact factor: 4.844

Review 7.  Risk of cardiovascular events associated with selective COX-2 inhibitors.

Authors:  D Mukherjee; S E Nissen; E J Topol
Journal:  JAMA       Date:  2001 Aug 22-29       Impact factor: 56.272

8.  Effects of selective cyclooxygenase-2 inhibition on vascular responses and thrombosis in canine coronary arteries.

Authors:  J K Hennan; J Huang; T D Barrett; E M Driscoll; D E Willens; A M Park; L J Crofford; B R Lucchesi
Journal:  Circulation       Date:  2001-08-14       Impact factor: 29.690

9.  Inhibition of cyclooxygenase-2 aggravates doxorubicin-mediated cardiac injury in vivo.

Authors:  N P Dowd; M Scully; S R Adderley; A J Cunningham; D J Fitzgerald
Journal:  J Clin Invest       Date:  2001-08       Impact factor: 14.808

Review 10.  Biochemistry of nitric oxide and its redox-activated forms.

Authors:  J S Stamler; D J Singel; J Loscalzo
Journal:  Science       Date:  1992-12-18       Impact factor: 47.728
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.